An interventional study of Family weight self-measurement and remote follow-up management based on wechat. and Routine care in Hemodialysis, Life Quality and Interdialytic Weight Gain, sponsored by qinxiu zhang. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by qinxiu zhang · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to Improve the quality of life in Hemodialysis patient. The main questions it aims to answer are:
Intervention group: On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients\' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →qinxiu zhang is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
Other: Routine care
On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
Other: Family weight self-measurement and remote follow-up management based on wechat.
On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
Adverse event rate
incidence of cardiovascular events (or hospitalization rate due to cardiovascular events such as hypertension and heart failure)
Time frame: 4, 8, and 12 weeks after intervention
Rate of completion
Completion rate of home self-measured weight combined with wechat intervention(including completion rate of home self-measured weight, completion rate of wechat intervention, and combination completion rate）
Time frame: 4, 8, and 12 weeks after intervention
dialysis related symptoms
(fatigue, weakness, pruritus, dialysis patient quality of Life scale)
Time frame: 4, 8, and 12 weeks after treatment
Laboratory index
hemoglobin
Time frame: 4, 8, and 12 weeks after treatment
level of Ga
Laboratory index
Time frame: 4, 8, and 12 weeks after treatment
level of P
Time frame: 4, 8, and 12 weeks after treatment
level of PTH
Time frame: 4, 8, and 12 weeks after treatment
level of K
Time frame: 4, 8, and 12 weeks after treatment
level of Na
Time frame: 4, 8, and 12 weeks after treatment
level of Cl
Time frame: 4, 8, and 12 weeks after treatment
concentration of albumin and prealbumin
Time frame: 4, 8, and 12 weeks after treatment
Laboratory index of total protein
Time frame: 4, 8, and 12 weeks after treatment
Dialysis efficiency \ dialysis adequacy (KTV)
Dialysis efficiency \\ dialysis adequacy (KTV)
Time frame: 4, 8, and 12 weeks after treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.